Reneo Reveals $50m Series A, Mitochondrial Disease Development Plans

 
• By Mandy Jackson

The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.

Hand man doing finances and calculate on desk about cost at home office.
Reneo will run three trials with its $50m in series A cash. • Source: Shutterstock

More from Financing

More from Business